- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
- Interventions
- COM701, COM701 with Opdivo (Nivolumab).
- Drug
- Lead sponsor
- Compugen Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Sarasota, Florida • Chicago, Illinois + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
- Interventions
- AZD6750, rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
- Conditions
- High-risk Muscle Invasive Urothelial Carcinoma
- Interventions
- Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 19
- States / cities
- Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Atezolizumab, Tiragolumab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Tempe, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 8 more
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • La Jolla, California • Hollywood, Florida + 7 more
- Conditions
- Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
- Interventions
- Domvanalimab, Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Whittier, California • Englewood, Florida + 15 more
- Conditions
- Hepatocellular Carcinoma, Biliary Tract Cancer
- Interventions
- Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 2 more
- Conditions
- Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
- Interventions
- Atezolizumab, Tocilizumab, Tiragolumab
- Biological
- Lead sponsor
- Alain Algazi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Interventions
- CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Detroit, Michigan • Reno, Nevada + 1 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Tiragolumab, Atezolizumab, Carboplatin, Etoposide, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Lone Tree, Colorado • Washington D.C., District of Columbia • Fort Myers, Florida + 15 more
- Conditions
- Multiple Myeloma, Relapsed Refractory Multiple Myeloma
- Interventions
- Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-TIGIT, Anti-TIGIT + Pomalidimide + Dexamethasone
- Drug
- Lead sponsor
- Multiple Myeloma Research Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
- Conditions
- Metastatic Solid Tumors
- Interventions
- M6223, Bintrafusp alfa
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee • Houston, Texas • San Antonio, Texas